MISC

2015年

How long should we continue S-1 as adjuvant chemotherapy for squamous cell carcinoma of the head and neck?

ACTA OTO-LARYNGOLOGICA
  • Misato Hirai
  • ,
  • Yorihisa Orita
  • ,
  • Soshi Takao
  • ,
  • Tomoyasu Tachibana
  • ,
  • Hidenori Marunaka
  • ,
  • Seiichiro Makihara
  • ,
  • Kentaro Miki
  • ,
  • Yasuyuki Noyama
  • ,
  • Sayaka Fuji
  • ,
  • Akiko Torigoe
  • ,
  • Yasuharu Sato
  • ,
  • Kazunori Nishizaki

135
10
開始ページ
1079
終了ページ
1085
記述言語
英語
掲載種別
DOI
10.3109/00016489.2015.1049664
出版者・発行元
TAYLOR & FRANCIS LTD

Conclusion: It appears that patients with SCCHN should be recommended to take S-1 for more than 1 year and, if possible, more than 2 years, as adjuvant chemotherapy for SCCHN. Objectives: There is no established consensus on the duration of administration of S-1 as adjuvant chemotherapy for squamous cell carcinoma of the head and neck (SCCHN). Since it might be difficult to undergo prospective randomized study to identify the optimal duration of the administration period of S-1 without a standard, the authors have undergone a retrospective clinical study to decide the tentative standard of therapeutic duration of S-1 as adjuvant chemotherapy for SCCHN. Methods: The clinical records of 89 patients with SCCHN who underwent adjuvant chemotherapy with S-1 were investigated. Results: The median duration of S-1 administration as adjuvant chemotherapy for SCCHN was 7 months (range = 0.1-58 months). Disease-free survivals (DFSs) were generally longer when S-1 administration periods were longer. After adjusting for prognostic factors, S-1 administration periods of 24 months or longer showed significantly lower hazard ratios (HRs) than 0-12 months.

Web of Science ® 被引用回数 : 2

リンク情報
DOI
https://doi.org/10.3109/00016489.2015.1049664
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000361294200017&DestApp=WOS_CPL

エクスポート
BibTeX RIS